Search

REGENXBIO Inc

Ouvert

SecteurSoins de santé

8.9 10.56

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.73

Max

8.66

Chiffres clés

By Trading Economics

Revenu

113M

23M

Ventes

102M

108M

BPA

0.43

Marge bénéficiaire

21.023

Employés

371

EBITDA

112M

34M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+175.68% upside

Dividendes

By Acuity

Prochains Résultats

5 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

128M

748M

Ouverture précédente

-1.66

Clôture précédente

8.9

Sentiment de l'Actualité

By Acuity

58%

42%

291 / 340 Classement par Healthcare

REGENXBIO Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 août 2026, 19:51 UTC

News
Social Media
Event

Regenxbio Inc shares are lower following the FDA's clinical hold on RGX-121 due to MRI findings, with Bank of America maintaining a $15 price target.

21 août 2026, 19:26 UTC

Regenxbio Inc shares are declining today amid notable volatility, pulling back significantly from an earlier peak during the session. No specific news was identified.

20 août 2026, 20:02 UTC

Regenxbio Inc. shares are lower as biotechnology stocks face pressure today, with no specific news identified to explain the decline.

19 août 2026, 22:06 UTC

Regenxbio Inc shares are higher in after-market trading, continuing a positive trend since Wednesday's close and remaining above their 20-day moving average.

18 août 2026, 19:46 UTC

Regenxbio Inc's shares are lower today amid rising Treasury yields and inflation concerns. The stock remains above its 20-day moving average.

17 août 2026, 20:06 UTC

Regenxbio Inc shares are higher today, reflecting strong market performance. The stock remains near its one-month high and above its 20-day moving average.

14 août 2026, 19:36 UTC

Regenxbio Inc shares are higher during Friday's session, advancing despite a reported decline in retail sales for July.

13 août 2026, 21:31 UTC

Regenxbio Inc shares are lower in after-market hours, pulling back from an earlier session high. No specific news was identified to explain the decline.

12 août 2026, 19:41 UTC

Regenxbio Inc shares are higher today amid positive market sentiment following a modest increase in the core Consumer Price Index.

11 août 2026, 19:11 UTC

Biotechnology stocks are advancing today, contributing to Regenxbio Inc's higher price movement. The stock pulled back earlier but remains in positive territory overall.

10 août 2026, 19:46 UTC

News

Regenxbio Inc shares are lower today after H.C. Wainwright cut its price target to $23.00, despite a strong Q2 earnings report.

7 août 2026, 20:06 UTC

News

Barclays downgraded Regenxbio Inc to Equal-Weight from Overweight, maintaining a $12 price target. Shares are trading lower amid concerns about growth prospects.

6 août 2026, 23:31 UTC

News

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

5 août 2026, 19:26 UTC

Regenxbio Inc shares are higher during Wednesday's session, despite intraday volatility. Broader market sentiment is influenced by a recent decline in crude oil prices.

4 août 2026, 19:56 UTC

Regenxbio Inc shares are higher, reflecting market strength amid a decline in crude oil prices that eased inflation concerns. No specific company news was identified.

31 juil. 2026, 19:36 UTC

Regenxbio Inc shares are lower, influenced by declines in the Biotechnology sector. The stock showed volatility, briefly rising earlier in the session.

30 juil. 2026, 19:29 UTC

Regenxbio Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday. The stock remains below its 20-day moving average.

29 juil. 2026, 19:56 UTC

Macro Event

Regenxbio Inc is trading higher as the Federal Reserve maintains interest rates, reflecting heightened market sensitivity amid ongoing economic growth and geopolitical tensions.

28 juil. 2026, 18:16 UTC

Regenxbio Inc shares are lower, continuing a three-day decline amid broader market pressures, including losses in Asian markets like the Nikkei 225 Index.

27 juil. 2026, 19:36 UTC

Regenxbio Inc is trading higher during Monday's session, recovering from earlier declines. Broader market sentiment is influenced by a significant drop in oil prices.

24 juil. 2026, 20:07 UTC

Regenxbio Inc shares are lower today, continuing a decline since Thursday's close. The stock remains below its 20-day moving average, indicating market weakness.

22 juil. 2026, 18:26 UTC

Regenxbio Inc shares are lower amid geopolitical tensions and rising crude oil prices. Earlier in the session, shares briefly recovered but have since declined.

21 juil. 2026, 19:31 UTC

Regenxbio Inc is higher during Tuesday's session, tracking the broader market's gains amid positive sentiment from recent earnings reports. No specific company news was identified.

20 juil. 2026, 19:31 UTC

Event
News
Social Media

Regenxbio shares rise after positive long-term trial results for surabgene lomparvovec, showing sustained vision improvements in patients with retinal conditions.

Comparaison

Variation de prix

REGENXBIO Inc prévision

Objectif de Prix

By TipRanks

175.68% hausse

Prévisions sur 12 Mois

Moyen 22.22 USD  175.68%

Haut 42 USD

Bas 10 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

7

Achat

2

Maintien

0

Vente

Sentiment

By Acuity

291 / 340Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
help-icon Live chat